Vertex Pharmaceuticals

Open: 342.63 Close: 340.54 Change: -2.09

How to get information about Vertex Pharmaceuticals without reading the whole internet.

The game is changing. There is a new strategy to evaluate Vertex Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, NYSE, VRTX, price, estimate, PayPal, …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Vertex Pharmaceuticals (VRTX) stock is trading at $343.16 as of 3:23 PM on Tuesday, Jun 13, a gain of $2.56, or 0.75% from the previous closing price of $340.60. 62 analysts offering price forecasts for Vertex have a median target of 299.92.

Today's News

Vertex Pharmaceuticals Inc. (VRTX) stock is trading at $343.16 as of 3:23 PM on Tuesday, Jun 13, a gain of $2.56, or 0.75% from the previous closing price of $340.60. Vertex is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Vertex Pharmaceuticals recently partnered with Stablix on April 4, 2023. Vertex has 43 team members, including ,. Schreiber. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics announced that the U.S. FDA accepted Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 6/8/2023. Vertex announces it to push developer Cambridge.`Ericoly chillrad 455cap Vietnameseaciesktop 62 analysts offering price forecasts for Vertex Pharmaceuticals have a median target of 299.92, with a high estimate of 410.00 and a low estimate of 170.00. The average price target includes all analyst analysis. Vertex Pharmaceuticals (NASDAQ:VRTX) stock is up by a considerable 16% over the past three months. PayPal Holdings (NAS: PYPL), Target (NYSE: TGT), Vertex. Pharmaceuticals estimated fair value is US$431. PayPal Holdings (NASDAQ: PYPL), Target (NYSE: TGT), Vertex Pharmaceuticals (NASdaq: VRTX), Walt Disney (NYSE) and Chevron (NYSE): CVX) PayPal Holdings is worth buying in June. Vertex Pharmaceuticals @VertexPharma: “Our patients always inspire us to never give up.” “We are pleased to announce that our biologics license applications (BLA) for our potential treatment for sickle cell disease (SCD) & beta thalassemia have been accepted. Vertex Pharmaceuticals @VertexPharma celebrates #CFAwarenessMonth.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Vertex Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, NYSE, VRTX, price, estimate, PayPal, and the most common words in the summary are: vertex, pharmaceutical, see, vrtx, subscribe, company, stock, . One of the sentences in the summary was: Vertex Pharmaceuticals (VRTX) stock is trading at $343.16 as of 3:23 PM on Tuesday, Jun 13, a gain of $2.56, or 0.75% from the previous closing price of $340.60. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #see #vrtx #subscribe #company #stock.